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ABSTRACT: We designed 3-aroyl-1,4-diarylpyrrole (ARDAP) derivatives as potential anticancer agents having different substitu-
ents at the 1- or 4-phenyl ring. ARDAP compounds exhibited potent inhibition of tubulin polymerization, binding of colchicine to 
tubulin and cancer cell growth. ARDAP derivative 10 inhibited the proliferation of BCR/ABL-expressing KU812 and LAMA84 cells 
from chronic myeloid leukemia (CML) patients in blast crisis and of hematopoietic cells ectopically expressing the imatinib mesylate 
(IM)-sensitive KBM5-WT or its IM-resistant KBM5-T315I mutation. Compound 10 minimally affected the proliferation of normal 
blood cells, indicating that it may be a promising agent to overcome broad tyrosine kinase inhibitor resistance in relapsed/refractory 
CML patients. Compound 10 significantly decreased CML proliferation by inducing G2/M phase arrest and apoptosis via a mito-
chondria-dependent pathway. ARDAP 10 augmented the cytotoxic effects of IM in human CML cells. Compound 10 represents a 
robust lead compound to develop tubulin inhibitors with potential as novel treatments for CML. 
Chronic myeloid leukemia (CML) is a myeloproliferative 
disease with an incidence of 1.8 new cases per 100,000 men and 
women per year.1 The hallmark of CML is the reciprocal trans-
location t(9;22)(q34;q11) (i.e., the Philadelphia chromosome, 
Ph) encoding for the hybrid protein BCR/ABL, a tyrosine ki-
nase with leukemogenic potential.2,3 At present, imatinib me-
sylate (IM, Gleevec), an inhibitor of both the BCR/ABL and c-
ABL tyrosine kinases, represents the treatment of choice for 
CML, inducing stable clinical remissions in more than 80% of 
newly-diagnosed patients. 
However, point mutations in the catalytic domain of the 
BCR/ABL oncoprotein4,5 or bcr/abl gene amplification6 can se-
lect IM-resistant clones in CML patients leading to a fatal blast 
crisis phase. Among the reported BCR/ABL point mutations, 
T315I (resulting in substitution of a threonine for an isoleucine 
residue at the ‘gatekeeper’ position 315) is of particular interest 
because it also provides resistance to clinically useful second-
generation tyrosine kinase inhibitors (TKIs) such as nilotinib, 
dasatinib and bosutinib.7 Therefore, there is a pressing need for 
devising novel combination regimens aimed at overcoming 
TKI-resistance in CML cells. 
 Microtubules are an attractive target for the development of 
effective anti-leukemia agents.8,9 Evidence has accumulated 
correlating inhibition of tubulin polymerization and leukemic 
cell proliferation.10-14 The activity of colchicine site agents in 
CML has not been adequately explored. In continuing our stud-
ies on tubulin targeting agents, we designed new 3-aroyl-1,4-
diarylpyrrole (ARDAP) derivatives (Chart 1, Table 1). 
 
 
Chart 1. ARDAP (1), ATI (2) and ARAP (3) derivatives. 
Docking studies on ARDAP prototype 1 showed that the pro-
posed binding mode was significantly different from those of 
its parent compounds ATI 215 and ARAP 3.16 However, the 
three compounds all shared the key interactions of the tri-
methoxyphenyl moiety with the Cys241 of tubulin (Figure 1). 
Observing the binding mode of ARDAP 1, we noticed that the 
N-phenyl pyrrole group of 1 was placed in the same position as 
the indole ring of 2, while the other ARDAP phenyl ring occu-
pied the same area as colchicine ring B.17 Based on these obser-
vations, we decided to investigate this new scaffold in search of 
novel tubulin binding agents. We planned the synthesis of a 
group of ARDAP derivatives bearing phenyl or substituted-
phenyl groups at positions 1 and 4 of the pyrrole nucleus (4-16, 
Table 1). In this study, we introduced on the phenyl rings sub-
stituents that were associated with the best biological activity in 
the ARAP series.16 
 
 
Figure 1. Proposed binding modes for 1 (orange stick), 2 (green), 
3 (cyan) and colchicine (gray) in the colchicine site. 
The new ARDAP derivatives were synthesized starting from 
chalcones 25-31, which were converted to the corresponding 
pyrrole derivatives 3216 or 33-39 with p-toluenesulfonylmethyl 
isocyanide (TosMIC). ARDAP compounds 1, 4-6, 8, 9, 12, 13, 
15, and 16 were obtained by reacting 3216 or 33-39 with the ap-
propriate boronic acid 40, 42, 43, 45 or 46. Reduction of 47 with 
Pd/C-H2 (1 atm) gave the ARDAP derivative 7. Tin(II) chloride 
treatment of nitro derivatives 48-50 furnished ARDAPs 10 and 
14 and compound 51, respectively. The latter compound was 
converted to ARDAP 11 with sodium nitrite in tetrafluoroboric 
acid. Reagents and reaction conditions are summarized in the 
Scheme 1 legend. 
In an initial screen, ARDAP 1 proved to be superior to 3 as 
an inhibitor of MCF-7 cell growth (Table 1). Besides the ability 
to inhibit tubulin polymerization, for which they were originally 
designed, we found that ARDAP compounds augment IM-
mediated apoptotic effects in BCR/ABL+ CML cells obtained 
from patients in blast crisis.  
ARDAP derivatives inhibited tubulin polymerization at mi-
cro- or submicromolar (4, 6, 7, 9 and 15) concentrations, as 
compared with colchicine (IC50 = 3.2 μM) and combretastatin 
A-4 (CSA4) (IC50 = 1.0 μM). Most ARDAP compounds po-
tently inhibited the growth of MCF-7 cells. ARDAPs 4, 7, 10, 
15 and 16 exhibited IC50 values ≤30 nM. 
Table 1. Inhibition of Tubulin Polymerization, Growth of 
MCF-7 Human Breast Carcinoma Cells, and Colchicine 
Binding by ARDAPs 4-16 and References 3, Colchicine and 
CSA4.a 
 
compd R1 R2 
Tubulinb 
IC50 ± SD 
(M) 
MCF-7c 
IC50 ± SD 
(nM) 
Inh. Colch. 
Bindingd 
(% ± SD) 
1 H H 1.1 ± 0.1 35 ± 7 66 ± 1 
4 H 2-F 0.58 ± 0.02 30 ± 7 72 ± 4 
5 H 3-Me 1.6 ± 0.04 450 ± 70 5.7 ± 5 
6 H 3-F 0.63 ± 0.004 57 ± 2 53 ± 0.7 
7 H 3-NH2 0.39 ± 0.05 28 ± 3 57 ± 0.7 
8 H 4-Me 2.2 ± 0.1 280 ± 40 24 ± 0.07 
9 H 4-F 0.76 ± 0.1 78 ± 4 47 ± 4 
10 H 4-NH2 1.2 ± 0.1 9.0 ± 2 81 ± 2 
11 2-F H 2.0 ± 0.1 85 ± 7 29 ± 5 
12 3-Me H 1.7 ± 0.09 120 ± 0 82 ± 2 
13 3-F H 2.9 ± 0.3 350 ± 90 42 ± 0.5 
14 3-NH2 H 1.1 ± 0.08 74 ± 6 82 ± 4 
15 4-Me H 0.88 ± 0.03 30 ± 0 79 ± 0.1 
16 4-F H 1.3 ± 0.1 15 ± 5 62 ± 2 
3e — — 1.5 ± 0.2 700 ± 200 80 ± 2 
Colch — — 3.2 ± 0.4 5 ± 1 — 
CSA4 — — 1.0 ± 0.1f,g 13 ± 3 98 ± 0.6 
aExperiments were performed in triplicate. bInhibition of tubulin 
polymerization. Tubulin was at 10 μM in the assembly assay. cIn-
hibition of growth of MCF-7 human breast carcinoma cells. dInhi-
bition of [3H]colchicine binding: tubulin, [3H]colchicine, inhibitor 
at 1:5:5 M. eLit.16 fCSA4 yielded an IC50 = 0.65 μM in an assay 
contemporaneous with the evaluations of ARDAPs 5 and 7, in 
which a different tubulin preparation was used. gCSA4 yielded an 
IC50 of 0.79 μM in an assay contemporaneous with the evaluations 
of 4, 6 and 9, in which a different tubulin preparation was used.  
 Compound 10 was the most potent MCF-7 cell growth inhib-
itor within the series with an IC50 of 9 nM. In general, inhibition 
of colchicine binding correlated with inhibition of tubulin 
polymerization and MCF-7 cell growth. The best tubulin as-
sembly inhibitor 7 (IC50 = 0.39 µM) inhibited the growth of 
MCF-7 cells with an IC50 of 28 nM and colchicine binding by 
57%. The best MCF-7 cell growth inhibitor 10 (IC50 = 9 nM) 
inhibited tubulin polymerization with an IC50 of 1.2 M and col-
chicine binding by 81% (Table 1). As inhibitors of the ovarian 
carcinoma cell lines OVCAR-8 and its cognate P-glycoprotein 
(Pgp) overexpressing line NCI/ADR-RES, compound 7 yielded 
IC50 values of 190 and 110 nM, and 16 of 180 and 110 nM, 
respectively. With the exception of CSA-4, the reference col-
chicine, vinorelbine, vinblastine and paclitaxel were quite weak 
inhibitors of the MDR cell line (Table 1S, Supporting Infor-
mation). 
 
Scheme 1. Synthesis of Compounds 1 and 4-16a 
 
aReagents and reaction conditions. (a) NaOH, EtOH, 25 °C, 24 
h, 59-89%; (b) TosMIC, NaH, DMSO/Et2O, 25 °C, 4 h, Ar, 21-
84%; (c) (1, 4, 5, 8, 9, 12, 13, 15, 16, 47 and 48) boronic acid 40, 
42, 43, 45 or 46, Cu(AcO)2, Et3N, DCE, reflux, Ar, 4-72%; (d) (49 
and 50) 41 or 44, CuBr, Cs2CO3, quinoline N-oxide, DMSO, 65 °C, 
6 h, Ar, 9 and 34%; (e) (7) H2, Pd/C, MeOH, 1 atm, 25 °C, 2 h, 
82%; (f) (10, 14 and 51) SnCl2.2H2O, MeCOOEt, reflux, 6 h, 47-
60%; (g) NaNO2, HBF4, 0 °C, 1 h, 13%. 
Compounds 7, 10 and 16 were evaluated for growth inhibi-
tion of the KYSE150 (esophageal squamous cell), THP-1 (acute 
monocytic leukemia), NB4 (acute promyelocytic leukemia), 
HT-29 (human colorectal adenocarcinoma), HCT116 (colon 
cancer) and HepG2 (liver hepatocellular) cell lines (Table 2S, 
Supporting Information). Derivative 10 was found to be the 
most potent compound, with IC50 values ranging from 20 nM 
(KYSE150 and HCT116) to 46 nM (HepG2). 
 
The most potent ARDAP derivative 10 was investigated for 
efficacy with BCR/ABL-expressing cells established in vitro 
from CML patients in blast crisis (KU812 and LAMA 84) com-
pared with previously reported colchicine site binders 2-(1H-
imidazol-1-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole19 
(52) and (1-(3-aminophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethox-
yphenyl)methanone16 (53). While derivatives 52 and 53 inhib-
ited CML cell growth (IC50) at concentrations ranging from 28 
to 35 nM, ARDAP derivative 10 was the most potent compound 
(IC50 = 12 and 14 nM, respectively) (Table 3S and Figure 3S, 
Supporting Information). These results demonstrate that high 
cytotoxicity can occur with compounds belonging to this new 
class of compounds. 
 A dose-dependent inhibition of proliferation was observed 
for KU812 and LAMA84 cells exposed to increasing doses of 
10 for 48 h, as assessed by MTT assays. Compound 10 inhibited 
CML cell growth by 50% at 12 nM. At such nanomolar concen-
trations, 10 minimally affected normal blood cells. Of note, pe-
ripheral blood mononuclear cells (PBMCs) isolated from 
healthy donors remained substantially insensitive to 10 up to 1 M (Figure 2). 
 
 
Figure 2. Compound 10 decreased CML cell proliferation at 
nanomolar concentrations without affecting normal PBMCs. 
Experiments were performed in triplicate. 
Based on the above data, by virtue of its anti-leukemic poten-
tial, we extended the analysis of biological effects of 10 to pro-
liferation and viability of IM-sensitive KBM5 and IM-resistant 
KBM5-T315I cells (Figure 3). By performing MTT assays, we 
found that 10 dose-dependently blocked growth of KBM5 and 
KBM5-T315I cells with similar average IC50 values of 15 and 
18 nM, respectively. The anti-leukemic activity of 10 in 
BCR/ABL+ cells expressing the T315I gatekeeper mutation in-
dicated that the drug may be a promising agent to overcome 
broad TKI-resistance in relapsed/refractory CML patients. 
 
 
 Figure 3. Cytotoxicity of 10 on CML cells ectopically ex-
pressing the IM-sensitive wild type KBM5-WT or its IM-
resistant KBM5-T315I mutation. Experiments were performed 
in triplicate. 
A rapid collapse of mitochondrial transmembrane potential 
was detected in KU812 cells exposed to 100 nM 10 for 8 h, to 
a greater extent as compared with those exposed to IM (100 nM 
for 8 h), as a consequence of the opening of permeability tran-
sition pores that accumulate a fluorescent dye from its red-ag-
gregated to its green-monomeric forms (Figure 4A, left panels). 
Specifically, a majority (97.8%) of solvent-treated KU812 cells 
had a bright red fluorescence, indicative of intact mitochondria, 
while 35.3% of 10-treated KU812 cells at 100 nM for 8 h ex-
hibited a marked green fluorescence indicative of damaged mi-
tochondria. Nuclear morphology of 10-treated KU812 cells was 
also evaluated using Hoechst-3258 staining (Figure 4B, right 
panels); a blue-to-cyan fluorescence was detected in most of the 
nuclei of 10-treated vs DMSO-control cells indicating their 
apoptotic morphology. Taken together, these data indicated that 
10 significantly decreased CML proliferation by inducing 
G2/M phase arrest and apoptosis via a mitochondria-dependent 
pathway. 
 
Figure 4. Compound 10 promotes CML cell death via mito-
chondrial-dependent pathways – comparsion with IM. Experi-
ments were performed in triplicate. 
We examined the ability of 10 to augment the cytotoxic ef-
fects of IM in human CML cells. To study this, LAMA84 cells 
were incubated for 48 h with increasing doses of IM (range 1-
1000 nM) in the absence or presence of 100 nM 10 and then 
analyzed by the MTT assay (Figure 5A). The combined regi-
men of IM and 10 was more effective than IM alone in reducing 
CML cell growth, lowering the IC50 value for IM from 100 nM 
to less than 10 nM. It had been reported previously that the av-
erage IC50 value for IM in LAMA84 cells overexpressing BCR-
ABL is 100 nM,4 and this was also observed here. Similar re-
sults were also obtained using KU812 cells (data not shown). In 
addition, the IM-resistant KBM5-T315I cells showed the same 
susceptibility to 10-induced cell death as well as IM-sensitive 
KBM5-WT cells, reaching respectively 58.2 ± 4.5% and 62.6 ± 
5.4% of annexin V+ cells at 48 h of drug exposure as compared 
to 2.2 ± 1.8% for control cells. Most importantly, exposure to 
100 nM 10 significantly augmented the pro-apoptogenic effects 
of IM, when annexin V-FITC staining was used to detect early 
cell death at 24 h (Figure 5B). 
Given that 10 interferes with tubulin function, we then exam-
ined cell morphological features under phase contrast micros-
copy and cell cycle distribution by flow cytometry (Figure 1S, 
Supporting Information). Compared to cell cultures incubated 
with DMSO as vehicle control (ctrl), KU812 cells treated with 
100 nM 10 showed an elongated shape and multiple centro-
somes typical of giant cells with failed cytokinesis and altered 
tubulin immunostaining (Figure 1S, Panel A). 
These characteristics, typically resembling those referred to 
as mitotic catastrophe, occurred at relatively early (2 to 8 h) ex-
posure intervals correlating with a net mitotic arrest of 10-
treated cells accumulated in the G2/M cell cycle phase (60.3 ± 
3.4% of treated vs 35.7 ± 2.8% of control cells), whereas apop-
totic cells in the subG1 phase did not exceed 10%. After a 24 h 
treatment, cell mitotic abnormalities disappeared in keeping 
with a reduced G2/M fraction reaching 11.4 ± 8.3%, whilst a 
massive apoptosis induction (peaking at 75.6 ± 11.4% of 10-
treated cells vs 0.4 ± 0.8% of control cells) indicated a greater 
susceptibility to death following the initial mitotic arrest (Figure 
1S, Panel B). 
 
 
Figure 5. Compound 10 potentiates IM-mediated cell death 
of CML cells, including those expressing the T315I mutation. 
Experiments were performed in triplicate. 
 
It is worth noting that IM, when used as a single agent at 100 
nM, was ineffective in altering CML KU812 cell shape or via-
bility, causing only a weak anti-proliferative effect at 24 h (56.3 
± 3.4% in IM-treated vs 42.7 ± 6.2% in DMSO-treated cells ar-
rested in the G1 phase of the cell cycle). As shown in Figure 1S, 
Panel C, the levels of the growth inhibitory protein p21Cip/WAF1 
were rapidly up-regulated after 6 h of 10 treatment and de-
creased after 24 h when the cleavage of the pro-apoptotic pro-
tein PARP indicated prominent activation. In keeping with this 
 observation, treatment with 10 also increased caspase-3 activa-
tion in a time-dependent fashion, as assessed by flow cytometry 
(Figure 1S, Panel D). 
To determine whether 10 interferes with BCR/ABL phospho-
activation and its signal transduction machinery, LAMA84 cells 
were cultured for 24 h in the presence of IM or 10, both at 100 
nM. Cells were then lysed and analyzed by Western immunob-
lotting (Figure 2S, Supporting Information). Treatment with 10 
did not alter auto-activation, while total levels of E-cadherin 
were substantially reduced compared to cells incubated with 
DMSO or IM. Compound 10 also reduced the active pools of 
unphosphorylated -catenin and phospho-cofilin without af-
fecting their total protein levels. Since -catenin and cofilin act 
as cytoskeletal adaptor proteins and are critical determinants of 
CML cell growth, it seems conceivable that these two mole-
cules may elicit the anti-leukemic potential of 10, beyond its 
expected effects on tubulin function. 
In conclusion, we synthesized ARDAP derivatives as poten-
tial anticancer agents. The new ARDAPs inhibited tubulin 
polymerization with IC50 values in the micro- or submicromolar 
concentration range. Most compounds inhibited the prolifera-
tion of human MCF-7 cells with IC50 values ≤30 nM. The most 
potent MCF-7 cell growth inhibitor within the series, 10 (IC50 = 
9 nM), proved to inhibit BCR/ABL-expressing KU812 and 
LAMA84 cells from CML patients in blast crisis and hemato-
poietic cells ectopically expressing the IM-sensitive KBM5-
WT or its IM-resistant KBM5-T315I mutation. The CML cell 
inhibition went through G2/M phase arrest and apoptosis via a 
mitochondria-dependent pathway. ARDAP 10 augmented the 
cytotoxic effects of IM in human CML cells. IM and 10 in com-
bination improved the effectiveness of IM alone in reducing 
CML cell growth, with a 10-fold decrease in the IC50 value for 
IM, from 100 nM to less than 10 nM. Overall, our results indi-
cate that compound 10 has potential as a novel drug to treat 
CML. On the basis of this valuable information, new ARDAP 
compounds are currently being synthesized with guidance from 
computational studies, and the results will be reported in due 
course. 
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